Literature DB >> 1657382

Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line.

N S Templeton1, W G Stetler-Stevenson.   

Abstract

A basal promoter for the Mr 72,000 type IV collagenase gene was specifically defined by chloramphenicol acetyltransferase assays of a nested set of 5' upstream fragments containing the promoter region. This core promoter is TACATCT and is a noncanonical TATA box that fits the TATA consensus sequence. This sequence begins 26 base pairs in the upstream direction from the start site of transcription for the type IV collagenase gene. This basal promoter is active in the highly metastatic A2058 melanoma cell line. A putative enhancer was found between nucleotides -223 to -422 that produces a 7-fold increase in transcriptional activity in the A2058 melanoma cell line. The region immediately 5' of the basal promoter, upstream to position -422, contains a silencer and represses transcriptional activity in the nonmetastatic HT144 melanoma cell line. The results of this study are consistent with previous data that found high expression of Mr 72,000 type IV collagenase mRNA and enzymatic activity in the A2058 cell line, whereas low mRNA expression and type IV collagenase activity were found in the HT144 cell line.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657382

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo.

Authors:  R E Sawaya; M Yamamoto; Z L Gokaslan; S W Wang; S Mohanam; G N Fuller; I E McCutcheon; W G Stetler-Stevenson; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

4.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Physiology and pathophysiology of matrix metalloproteases.

Authors:  T Klein; R Bischoff
Journal:  Amino Acids       Date:  2010-07-18       Impact factor: 3.520

Review 6.  Role of Gelatinases MMP-2 and MMP-9 in Healthy and Complicated Pregnancy and Their Future Potential as Preeclampsia Biomarkers.

Authors:  Asparuh Nikolov; Nikola Popovski
Journal:  Diagnostics (Basel)       Date:  2021-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.